Michael J. Birrer, MD of Massachusetts General Hospital discusses PDL-1 and immune checkpoint inhibitors in endometrial cancer at SGO 2016.
And the short answer is not a lot and meet your cancer. Has not been one of the first tumors explored for immunotherapy a really was melanoma and real sal. The second wave is involving ovary and. Other tumors in endometrial is probably closer to the third wave. Suffice it to say PT one is expressed. Our and it's likely that PPL one will also be expressed. We have no clue whether that's predictive. For. Response.
Michael J. Birrer, MD of Massachusetts General Hospital discusses promising immunotherapy currently under evaluation for advance gynecologic cancers at SGO 2016.
Well I think the checkpoint hitters are the hot ones partly because they they've got eggs terrific track record and other tumors into easy to give their antibodies but it's been a long track record of immunotherapy. In gynecologic cancers the the. Pennsylvania group where George Lucas was now Georges and in Switzerland was doing adopted TCL approaches and there were some promising results with that the problem is it's it's. Resource intensive credibly expensive and toxic. But that's still being at still being approach Carty. Which has had a very impressive splash with childhood. Cancers I know for a fact there's a trial in ovarian cancer targeting I believe mesothelioma has the target. Cleanly done say up in Roswell has multiple immunotherapy trials. Some of which are vaccine based. I think one of the clever approaches which we are trying to design now in other centers are is. To take over in cancer the time of of the bulking so there's lots of tumor and do whole Exum sequencing.
B.J. Rimel, MD of Cedars Sinai Medical Center discusses the SGO 2016 highlights and trends from SGO 2016.
I think that the array of options. For testing whether it be genetic panel testing with multiple multiple genes. Or is it a ray of immunotherapy auctions are probably the two strongest trends I see here at this meeting. There's a lot of work that remains to be done to see how that's going to play out for patients I think that clinicians and providers. And patients need to be aware of these options before we run headlong into these be aware of the risks the benefits. The potential outcomes both good and bad I think clinical trials are incredibly valuable as we start all the stuff out elements are really appreciate all the patients that devote themselves to being on a clinical trial.
Michael J. Birrer, MD of Massachusetts General Hospital discusses HPV-related cervical cancer with anti-PD-1 and anti-PDL-1 antibodies at SGO 2016.
So I think from a theoretical standpoint. Cervical cancer should be the poster child for immunotherapy. I sencha understand these tumors. Result in infection from HP vis vis vis vis genome is there E. seven any six are usually expressed these are foreign and agents these are viral infections. So if the immune system is. Op inactivated. Ended tumors producing some of these in him dory prophecies if you use an anti PDL-1 one or anti PD-1 you should. Wake up the immune system and it should be effective.